We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Cell line enhanced (HDLM-2)
HPA (normal tissue):
Expressed in all
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Caution, targets protein from more than one gene. Pending external verification.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
Cases of breast cancers showed weak to moderate cytoplasmic staining. Remaining cancers were generally negative.
Several hepatocellular carcinomas, urothelial cancers and melanomas along with a few gliomas and colorectal cancers displayed weak to moderate cytoplasmic and/or nuclear positivity. Cases of lung adenocarcinomas showed moderate to strong staining. Remaining cancers were negative.
Most cancers showed weak to moderate cytoplasmic immunoreactivity. Carcinoids, liver, prostate and skin cancers along with most lymphomas, testicular and lung cancers were negative.
Several carcinoids, lymphomas, melanomas, thyroid, urothelial and breast cancers along with few colorectal, stomach and skin cancers displayed moderate nuclear staining with occasional cytoplasmic positivity. Other cancer tissues were generally weakly stained or negative.
GENE INFORMATIONi
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
Gene name
STAT5B
Synonyms
Description
Signal transducer and activator of transcription 5B (HGNC Symbol)
Entrez gene summary
The protein encoded by this gene is a member of the STAT family of transcription factors. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein mediates the signal transduction triggered by various cell ligands, such as IL2, IL4, CSF1, and different growth hormones. It has been shown to be involved in diverse biological processes, such as TCR signaling, apoptosis, adult mammary gland development, and sexual dimorphism of liver gene expression. This gene was found to fuse to retinoic acid receptor-alpha (RARA) gene in a small subset of acute promyelocytic leukemias (APLL). The dysregulation of the signaling pathways mediated by this protein may be the cause of the APLL. [provided by RefSeq, Jul 2008]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
STAT5B-001
STAT5B-003
PROTEIN INFORMATIONi
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
P51692 [Direct mapping] Signal transducer and activator of transcription 5B
Show all
Predicted intracellular proteins Transcription factors Immunoglobulin fold Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Somatic Mutations COSMIC Other Mutations COSMIC Missense Mutations COSMIC Translocations Disease related genes Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000255 [allantoin metabolic process] GO:0000979 [RNA polymerase II core promoter sequence-specific DNA binding] GO:0001077 [transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding] GO:0001553 [luteinization] GO:0001779 [natural killer cell differentiation] GO:0003677 [DNA binding] GO:0003682 [chromatin binding] GO:0003700 [transcription factor activity, sequence-specific DNA binding] GO:0004713 [protein tyrosine kinase activity] GO:0004871 [signal transducer activity] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005737 [cytoplasm] GO:0005829 [cytosol] GO:0006101 [citrate metabolic process] GO:0006103 [2-oxoglutarate metabolic process] GO:0006105 [succinate metabolic process] GO:0006107 [oxaloacetate metabolic process] GO:0006351 [transcription, DNA-templated] GO:0006355 [regulation of transcription, DNA-templated] GO:0006357 [regulation of transcription from RNA polymerase II promoter] GO:0006366 [transcription from RNA polymerase II promoter] GO:0006549 [isoleucine metabolic process] GO:0006573 [valine metabolic process] GO:0006600 [creatine metabolic process] GO:0006631 [fatty acid metabolic process] GO:0007165 [signal transduction] GO:0007259 [JAK-STAT cascade] GO:0007548 [sex differentiation] GO:0007565 [female pregnancy] GO:0007595 [lactation] GO:0008284 [positive regulation of cell proliferation] GO:0018108 [peptidyl-tyrosine phosphorylation] GO:0019218 [regulation of steroid metabolic process] GO:0019221 [cytokine-mediated signaling pathway] GO:0019530 [taurine metabolic process] GO:0019903 [protein phosphatase binding] GO:0019915 [lipid storage] GO:0030155 [regulation of cell adhesion] GO:0030856 [regulation of epithelial cell differentiation] GO:0032355 [response to estradiol] GO:0032819 [positive regulation of natural killer cell proliferation] GO:0032825 [positive regulation of natural killer cell differentiation] GO:0032870 [cellular response to hormone stimulus] GO:0033077 [T cell differentiation in thymus] GO:0035259 [glucocorticoid receptor binding] GO:0038161 [prolactin signaling pathway] GO:0040014 [regulation of multicellular organism growth] GO:0040018 [positive regulation of multicellular organism growth] GO:0042104 [positive regulation of activated T cell proliferation] GO:0042448 [progesterone metabolic process] GO:0043029 [T cell homeostasis] GO:0043066 [negative regulation of apoptotic process] GO:0045086 [positive regulation of interleukin-2 biosynthetic process] GO:0045579 [positive regulation of B cell differentiation] GO:0045588 [positive regulation of gamma-delta T cell differentiation] GO:0045621 [positive regulation of lymphocyte differentiation] GO:0045647 [negative regulation of erythrocyte differentiation] GO:0045648 [positive regulation of erythrocyte differentiation] GO:0045931 [positive regulation of mitotic cell cycle] GO:0045944 [positive regulation of transcription from RNA polymerase II promoter] GO:0045954 [positive regulation of natural killer cell mediated cytotoxicity] GO:0046449 [creatinine metabolic process] GO:0046543 [development of secondary female sexual characteristics] GO:0046544 [development of secondary male sexual characteristics] GO:0046983 [protein dimerization activity] GO:0048541 [Peyer's patch development] GO:0050729 [positive regulation of inflammatory response] GO:0060397 [JAK-STAT cascade involved in growth hormone signaling pathway] GO:0070669 [response to interleukin-2] GO:0070670 [response to interleukin-4] GO:0070672 [response to interleukin-15] GO:0071363 [cellular response to growth factor stimulus] GO:0071364 [cellular response to epidermal growth factor stimulus] GO:0097531 [mast cell migration]
C9J4I3 [Direct mapping] Signal transducer and activator of transcription 5B
Show all
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Somatic Mutations COSMIC Other Mutations COSMIC Missense Mutations COSMIC Translocations Protein evidence (Ezkurdia et al 2014)
The Human Protein Atlas project is funded
MENU
